SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* K/S Danish BioVenture (Last) (First) (Middle) 12 H.C. ANDERSENS BLVD (Street) COPENHAGEN, DENMARK (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/30/2014	3. Issuer Name and Ticker or Trading Symbol Paratek Pharmaceuticals, Inc. [ PRTK ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	633,243	D(1)(2)
Common Stock	633,243	I	By Danish BV(1)(3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Purchase)	04/18/2014	04/18/2021	Common Stock	2,329	$0.15	D(1)(2)
Warrant (Right to Purchase)	04/18/2014	04/18/2021	Common Stock	2,329	$0.15	I	By Danish BV(1)(3)

1. Name and Address of Reporting Person* K/S Danish BioVenture (Last) (First) (Middle) 12 H.C. ANDERSENS BLVD (Street) COPENHAGEN, DENMARK (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Danish BioVenture General Partner ApS (Last) (First) (Middle) 12 H.C. ANDERSENS BLVD (Street) COPENHAGEN, DENMARK (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. The Reporting Persons are part of a "group" as defined in Rule 13d-5 promulgated under the Securities Exchange Act of 1934, as amended, with the following entities and individuals: Omega Fund III, L.P.; Omega Fund III GP, L.P.; Omega Fund III GP, Ltd.; Omega Fund IV, L.P.; Omega Fund IV GP, L.P.; Omega Fund IV GP Manager, Ltd.; Omega Fund Management Limited; Sigma Holding Company; and Otello Stampacchia. This group beneficially owns, in the aggregate, 2,138,872 shares of common stock of the issuer and warrants to purchase an additional 6,412 shares of common stock of the issuer.

2. The reported securities are held in the name of K/S Danish BioVenture ("Danish BV"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein.

3. The reported securities are beneficially owned by Danish BioVenture General Partner ApS ("Danish BV GP"), as the general partner of Danish BV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein.

Remarks:

	/s/ Richard Lim, authorized signatory of each Reporting Person	11/10/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.